Apalutamide toxicity and tolerability: A real-world multicentre experience in metastatic hormone-sensitive prostate cancer (MHSPC) in the United Kingdom (UK).

被引：0
|
作者：
Ramamurthy, Sindhu
Elumalai, Thiraviyam
Pearson, Rachel
Bolnykh, Iakov
Muhammad-Afzal, Tehreem
Olukiran, Gbenro
Arora, Ananya
Bradley, Gay
Taft, Kate
Myint, Nayan Lin
Htike, Ei The
Ince, Will
Jiang, Xue Yan
机构：
[1] United Lincolnshire Hosp NHS Trust, Lincoln, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[3] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] United Lincolnshire Hosp NHS Trust, Grantham, England
[5] Univ Cambridge, Sch Med, Cambridge, England
[6] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-2494-5577-5578; 613-615-646-3281-7408-2638; 261-492-199; 130-3426-5390-2622; 130-3426-3529; 283-2494; 613-302-309; 6; 5; 4; 3; 2; 1917; 8;
D O I：
10.1200/JCO.2024.42.4_suppl.107
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    Current Treatment Options in Oncology, 2019, 20
  • [22] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [23] Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study
    Kafka, Mona
    Giannini, Giulia
    Artamonova, Nastasiia
    Neuwirt, Hannes
    Ofner, Heidemarie
    Kramer, Gero
    Bauernhofer, Thomas
    Luger, Ferdinand
    Hoefner, Thomas
    Loidl, Wolfgang
    Griessner, Hubert
    Lusuardi, Lukas
    Bergmaier, Antonia
    Berger, Andreas
    Winder, Thomas
    Weiss, Sarah
    Bauinger, Severin
    Krause, Steffen
    Drerup, Martin
    Heinrich, Elmar
    Schneider, Magdalena
    Madersbacher, Stephan
    Vallet, Sonia
    Stoiber, Franz
    Laimer, Sarah
    Hruby, Stephan
    Schachtner, Gert
    Nagele, Udo
    Lenart, Sebastian
    Ponholzer, Anton
    Pfuner, Jacob
    Wiesinger, Clemens
    Kamhuber, Christoph
    Muelduer, Ecan
    Bektic, Jasmin
    Horninger, Wolfgang
    Heidegger, Isabel
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 458 - 466.e1
  • [24] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    UROLOGIE, 2023, 62 (04): : 441 - 442
  • [25] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients
    Sudhakaran, Gokul
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [27] Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study
    Yanagisawa, Takafumi
    Fukuokaya, Wataru
    Hatakeyama, Shingo
    Narita, Shintaro
    Muramoto, Katsuki
    Katsumi, Kouta
    Takahashi, Hidetsugu
    Urabe, Fumihiko
    Mori, Keiichiro
    Tashiro, Kojiro
    Iwatani, Kosuke
    Shimomura, Tatsuya
    Habuchi, Tomonori
    Kimura, Takahiro
    PROSTATE, 2025, 85 (02): : 165 - 174
  • [28] Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.
    Raval, Amit D.
    Chen, Guifang
    Korn, Matthew J.
    Bernthaler, Andreas
    Constantinovici, Niculae
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [29] DAROLUTAMIDE REAL-WORLD DOUBLET AND TRIPLET UTILIZATION IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC): US COMMUNITY UROLOGY SETTING
    Lowentritt, Benjamin
    Curry, Lauren
    Singh, Rakesh
    Lazarou, Nicholas
    O'Donnell, Lorraine
    Eller, James
    Grant, Katie
    Arango-Hisijara, Israel
    Kalayeh, Bashir
    Kirkwold, Jeff
    Himes, Audrey
    Jhaveri, Jay
    Hamilton, Joelle
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1007 - E1008
  • [30] Latin American patient subgroup analysis of the phase 3 TITAN study: Apalutamide plus ADT in metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
    Juarez, Alvaro
    Chi, Kim N.
    Pereira, Andrea J.
    Chowdhury, Simon
    Triantos, Spyros
    McCarthy, Sharon
    Bhaumik, Amitabha
    Mundle, Suneel
    Velasquez, Esteban
    Rosas, Sara
    Fabricio, Vanessa
    Agarwal, Neeraj
    CANCER RESEARCH, 2021, 81 (13)
12345